بوکولوم (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "بوکولوم" in Persian language version.

refsWebsite
Global rank Persian rank
2nd place
2nd place
4th place
5th place
207th place
287th place
11th place
52nd place

doi.org

  • Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.
  • Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.
  • Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.
  • Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.
  • Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

psu.edu

citeseerx.ist.psu.edu

  • Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.

semanticscholar.org

api.semanticscholar.org

  • Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.